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Abstract
Acute kidney injury (AKI) is a prevailing health threat around the world with high mor-
talities and heavy economic burdens. In the past, apoptosis was recognized as the main 
contributor to the pathogenesis of AKI. However, recent evidence has suggested that 
regulated necrosis also plays an important role in the pathologic process of various types 
of renal damages, improving our limited understanding of the complex mechanisms 
underlying AKI. Regulated necrosis is a newly identified type of “programed cell death” 
with morphologic features of necrosis, which includes necroptosis, ferroptosis, parthan-
atos, pyroptosis, etc. In this chapter, we summarized the molecular pathways of both 
apoptosis and regulated necrosis, and reviewed the potential roles and corresponding 
mechanisms of various cell deaths in AKI based on recent advances. We also discussed 
the therapeutic potentials and clinical implications based on manipulating regulated cell 
death. Taken together, the progress in this field lays the ground for better prevention and 
management of AKI in the future.
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1. Introduction
The balance between cell survival and cell death laid the foundation for any individual organ-
isms. Cell death, especially molecularly regulated cell death, has been extensively investigated 
for decades in life science and medicine. Historically, cell death was roughly classified as dif-
ferent types: apoptosis and necrosis [1]. The term “apoptosis” derives from ancient Greek and 
refers to the developmentally programmed and molecularly controlled cell death, with fea-
tured morphologic changes including cell shrinkage, nuclear and cytoplasmic condensation, 
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DNA fragmentation, and the formation of apoptosomes [2]. Necrosis, differently, was well 
recognized as an accidental cell death, with unique characteristics consisting of cellular swell-
ing, breakdown of plasma membrane integrity, and release of intracellular contents, all of 
which are absolutely distinct from programmed cell death [3].
Caspase-dependent apoptosis is the first identified programmed form of cell death and was 
regarded as the only form of regulated cell death for a very long time. However, this restricted 
view has been challenged with the findings of new types of regulated cell death. Exciting break-
throughs in recent years have identified a group of novel forms of cell death, with morphologic 
features of necrosis but molecularly controlled, termed regulated necrosis [4]. According to the 
recommendations of Nomenclature Committee on Cell Death (NCCD), the types of regulated 
necrosis are composed of necroptosis, mitochondrial permeability transition (MPT)-mediated 
regulated necrosis (MPT-RN), parthanatos, ferroptosis, and pyroptosis [5]. Nowadays, it is 
well documented that regulated necrosis broadly participates in various biological processes 
including organism development, immune defenses and various pathophysiological processes 
[4, 6]. An accumulating body of evidence has demonstrated that regulated necrosis contributes 
to the pathogenesis of numerous diseases and damages in different organs or tissues [4, 6, 7].
Acute kidney injury (AKI), with a heavy health burden globally, still remains a severe condi-
tion in daily clinical routines to date [8]. It is estimated that every year approximately 13.3 mil-
lion people are diagnosed with AKI and AKI contributes to about 1.7 million deaths around 
the world per year [9]. In the past, apoptosis was supposed as the predominant form of cell 
demise that is responsible for renal dysfunction during AKI [10]. Much study in recent years 
have indicated that programmed form of cell death, no matter apoptosis or regulated necro-
sis, plays an important role in keeping kidney tissue homeostasis as well as contributing to 
the pathogenesis of AKI [11, 12]. Different methods targeting the apoptotic molecular signals 
have been widely explored for AKI treatment. In spite of the solid protective effects of these 
treatments observed in animal models, the experimental anti-apoptosis intervention strate-
gies cannot still be translated into medical practice, which might be, at least partially, due to 
our ignorance of regulated necrosis in the process of AKI. An improved understanding of the 
pathogenesis of AKI under the view of regulated cell death might provide potential therapeu-
tic regimens based on manipulating both apoptotic and regulated necrotic pathways.
Therefore, in this chapter, we summarized the molecular pathways of both apoptosis and reg-
ulated necrosis, and reviewed the potential roles and corresponding mechanisms of various 
cell deaths in AKI based on recent advances. We further discussed the therapeutic potentials 
and clinical implications from the clinician’s underground.
2. Apoptosis in AKI
2.1. Signaling pathways of apoptosis
The classic apoptosis can be activated by the intrinsic and extrinsic pathways that both 
rely on the involvements of caspases [13]. To date, the signaling pathways of apoptosis 
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have been well delineated and for the integrity of the present review, we only emphasize 
on the basic and major signal events of classic apoptosis. The mitochondria are the cru-
cial converging site for the intrinsic and extrinsic signaling [14]. And specifically, mito-
chondrial outer membrane permeabilization (MOMP) serves as the key to initiate the final 
steps of apoptosis. MOMP results in the release of pro-apoptotic components of mitochon-
dria, including cytochrome c, AIF, etc., and thereby the activation of subsequent apoptotic 
executive mediators [15]. MOMP can be regulated by BCL2 family proteins consisting of 
pro- and anti-apoptotic factors [10]. Bax and Bak are the main members of BCL2 fam-
ily and serve as promoters for MOMP; Bcl-2 and Bcl-XL, in contrast, play just the oppo-
site role. Notably, the balance between the two parts determines the fates of cells. In the 
intrinsic pathway, several cellular stresses including DNA damage, intracellular calcium 
overload and growth factor ablation can directly induce MOMP. In response to the release 
of cytochrome c, apoptosome consisting of caspase 9, Apaf-1 and cytochrome c is formed 
in plasma, which initiates the execution of apoptosis. In the extrinsic pathway, ligation of 
death receptors results in the formation of DISC, which recruits adapter proteins subse-
quently leading to combination of caspase-8/FLIP heterodimer and caspase-8 homodimer. 
The homodimer then cleaves effector proteins caspases-3, -6 and -7 and thereby finishes the 
execution of apoptosis [16]. It is worthy to note that the extrinsic pathway is able to amplify 
the apoptotic signals by initiating the intrinsic pathway through caspase-8-independent 
activation of tBid, which can cause MOMP [14].
2.2. The contribution of apoptosis to AKI
As early as 1992, Schumer et al. have demonstrated the first evidence for the existence of 
apoptosis in AKI with morphologic, biochemical, and molecular detection methods [17]. 
Thereafter, studies about the role of apoptosis AKI and relevant potential therapeutic modali-
ties have been under intensive investigations. Overwhelming reports exhibited that apoptosis 
is functionally relevant to various kinds of AKI, of which ischemia–reperfusion injury (IRI) 
is the most well documented [18, 19]. Besides, sepsis is another common cause of AKI, espe-
cially in the intensive care units. Studies demonstrated that apoptosis serves as an important 
foundation for the pathogenesis of sepsis-related AKI [20–22]. In addition to IRI and septic 
renal injury, toxic kidney injury is also a common clinical condition contributing to a high rate 
of morbidity and mortality. Cisplatin, for instance, is a widely-used chemotherapy drug with 
relatively high nephrotoxicity. As supposed, apoptosis plays a vital role in the pathologic 
process of toxic renal injury [23].
In the context of AKI, apoptotic cells are detected in different types of renal tissues within 
both cortical and medullary regions. The most common sites are the renal tubules, especially 
the proximal tubules [10]. Besides, AKI can also cause apoptosis in other renal cells, for exam-
ple the vascular endothelial cells which in turn deteriorate kidney damages [24, 25].
Collectively, these studies proved the widely occurrence and definitely great functional con-
tributions of renal apoptosis during AKI. The apoptosis was supposed as the most prominent 
cell death in AKI for nearly two decades, until increasing evidence shows regulated necrosis 
is to great extent responsible for the pathogenesis of AKI as well.
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3. Necroptosis in AKI
3.1. The signaling pathways of necroptosis
Necrostatin-1 (Nec-1) was identified as a specific inhibitor of receptor-interacting protein 
kinase 1 (RIP1) in 2008. Since then, the molecular pathways of necroptosis have been exten-
sively studied [26, 27]. As the best-characterized regulated necrosis, necroptosis is shown 
to be initiated by the engagement of death receptors, Toll-like receptors (TLRs), interferon 
signals, as well as intracellular stimuli from protein DNA-dependent activator of IFN regu-
latory factors (DAI) [28]. The details about the signaling of necroptotic cell death have been 
already reviewed [7, 28], and in this character, we only present the molecular pathways of 
TNF-α-induced necroptosis in the absence of functional caspases. Upon the binding of TNF-α 
to TNF receptor (TNFR)1, the adaptor molecules Fas-associated death domain (FADD) and 
TNF-receptor-associated death domain (TRADD) are recruited to the ligated TNFR1 succes-
sively. These adaptor molecules then bind to RIP1. Subsequently, RIP1 combines with RIP3 
to assemble a complex termed “necrosome” via the interaction of RIP homotypic interac-
tion motif (RHIM) domain on both RIP1 and RIP3 [29–32]. RIP3 goes through autophos-
phorylation within necrosome, which leads to the activation of RIP3 [30, 31]. Activated RIP3 
subsequently recruits and phosphorylates the downstream MLKL, which is believed as the 
executor of necroptosis [33, 34]. The exact mechanisms underlying the execution activity of 
MLKL are not totally delineated yet. It is thought that phosphorylated MLKL goes through 
a molecular switch to translocate to the membrane and consequently disrupt the integrity of 
plasma membrane to finish the action of necroptosis [35, 36]. In addition, study showed that 
MLKL could also induce mitochondria fission via the action of phosphoglycerate mutase 
family member 5 (PGAM5) and dynamin-related protein 1 (Drp-1) [37]. As mitochondria 
play an important role in apoptosis, this result suggests a broad involvement of mitochon-
dria in different types of cell death. But the relative contribution of mitochondria-mediated 
damages in the background of necroptosis needs further confirmation [38]. It is notable that 
other necroptotic pathways mediated by TLRs, interferon signals and DAI converge on the 
RIP3 and share the same downstream executing pathway, indicating the indispensable role 
of MLKL in necroptosis.
3.2. The contribution of necroptosis to AKI
In 2012, Linkermann and colleagues found the protective effect of Nec-1, the first-generation 
of necrostatins, in a murine model of renal IRI, providing the first evidence of the presence 
of necroptosis in AKI [39]. In this study, Nec-1 was shown to prevent ischemic kidneys from 
renal dysfunction and tissue damage, indicating both functional and histological relevance 
of necroptosis in the pathogenesis of AKI. The pan-caspase inhibitor zVAD that was used 
to inhibit apoptosis in treatment of kidney diseases, surprisingly, was demonstrated non-
protective in the same research. The reasons of this conflict result compared with a previous 
report that demonstrated the protective effect of zVAD in the context of IRI need further 
investigations [40]. The different methods adopted in these two independent researches may 
partially explain the incontinence of the therapeutic effects of zVAD. First, different clamping 
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time of the renal pedicles in these studies might result in the alterations of the magnitude 
of apoptotic and necroptotic cell death, which subsequently leads to a changed treatment 
effect. In addition, the time courses of the zVAD administration were also different. The pro-
files of cellular death kidneys will continuously evolve during AKI and apoptosis does not 
occur immediately after the onset of ischemia [10]. Therefore, application of zVAD just 15 min 
before ischemia might diminish its therapeutic effect. In accordance with this research, the 
protection of Nec-1 in rat and human renal tubular epithelia cells (TECs) against ischemic 
insults was confirmed by other investigators in vitro [41, 42]. Importantly, more convincing 
evidence of necroptosis in renal IRI was provided by using the Rip3-knockout mice in the 
following study. Linkermann et al. exhibited that Rip3-knockout mice improved kidney dam-
ages in contrast to wild-type mice, and Nec-1 administration in Rip3-knockout mice could not 
lead to addictive protection [43].
Besides IRI, accumulating evidence demonstrated necroptosis also contributes to AKI induced 
by nephrotoxic agents, including cisplatin, cyclosporin A (CsA) and imaging contrast. Tristao 
et al. found that Nec-1 can provide additional protection against the cisplatin-associated dam-
age on human renal TECs on the basis of zVAD treatment [44]. Later, Linkermann [43] and 
Xu [45] further provided more reliable evidence to confirm the role of necroptosis in cisplatin-
induced AKI with Rip3- and Mlkl-knockout mice models respectively. Ouyang et al. showed that 
rat TECs subjected to CsA, a widely used immunosuppressive drug for organ transplantation 
and other autoimmune diseases, were effectively protected by Nec-1 and knockdown of Rip3, 
indicating a role of necroptosis in the pathologic process of CsA-related AKI [46]. Furthermore, 
Nec-1 was similarly shown to prevent from contrast-induced AKI in a following study [47].
The existence of necroptosis was also indicated in a glycerol-induced rhabdomyolysis model 
[48]. The authors found that treatment with Nec-1 led to a reduced tubular necrosis, under-
scoring the importance of TNF-alpha-mediated tubular necroptosis in this model [48].
Taken together, these findings demonstrated that necroptosis is of vital importance for the 
pathogenesis of various types of AKI, suggesting a potential therapeutic checkpoint which 
invite further investigations basically and clinically.
4. Other regulated necrosis in AKI
4.1. MPT-RN
Mitochondrial permeability transition (MPT) mediated regulated necrosis (MPT-RN) is fea-
tured by the opening of a trans-mitochondrial membrane pore, namely the MPT pore (MPTP) 
[49]. CypD is identified as a controller of MPTP, which promotes the opening of this channel 
[50]. CypD interacts with another regulator the F
0
F
1
ATP synthase that maintains the inactiva-
tion of MPTP. Although the upstream pathways that initiate MPT-RN and the exact mecha-
nisms to modulate the activity of CypD and F0F1ATP synthase remain elusive, it is believed 
that the opening of MPTP is capable to result in translocation of NAD+ to cytosol and mito-
chondrial potential disruption [51]. NAD+ along with ATP can be further consumed in the 
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process of NAD+ glycohydrolases. The final result of these physiopathological alterations is 
the occurrence of regulated necrosis. Therapeutically, MPT-RN can be inhibited by sanglifeh-
rin A and cyclosporin A [52].
Several independent groups of investigators have demonstrated the role of MPT-RN in AKI by 
detecting the contribution of CypD in the pathogenesis of kidney injuries. In 2009, Devalaraja-
Narashimha et al. found that renal function, as well as the magnitude of erythrocyte trap-
ping, tubular cell necrosis, tubular dilatation, and neutrophil infiltration in kidney histology 
improved significantly in CypD-deficient mice in the background of renal ischemia–reperfu-
sion injury compared with wild-type mice [53]. Later, Hu et al. showed that knockdown of 
CypD by RNA interference could also protects rats from renal IRI [54]. The protective effects 
of CypD inhibition against kidney IRI in vitro and in vivo were further confirmed by Park 
et al. using a mouse model null for Ppif, the gene encoding CyPD [55]. Linkermann et al. 
evaluated CypD-deficient mice and RIP3-deficient mice in renal IRI and found that RIP3 dele-
tion seemed to offer a better protection, providing a direct comparison between the selective 
contributions of MPT-RN and necroptosis to renal IRI [43]. More importantly, the researchers 
also showed CypD-RIPK3 double-knockout or combined application of Nec-1 and sanglifeh-
rin A were more protective than inhibiting either of these two genes alone, indicating the 
coexistence of independent regulated necrosis in the same physiopathologic process.
4.2. Parthanatos
Parthanatos is the poly(ADP-ribose) polymerase 1 (PARP1)-dependent regulated necrosis 
[56]. PARPs cause the poly(ADP-ribosyl)ation (PARylation) of target proteins and thereby 
regulate various cellular bioactivities [57]. Different stimuli such as DNA breaks and Ca2+ 
signaling can activate PARP1, which induces the accumulation of PAR polymers. Both PARP1 
and PAR polymers are able to delete NAD+ and ATP via their PARylation [58, 59].
Increasing body of researches have demonstrated that parthanatos plays an important role 
in the pathogenesis of various types of AKI. By using genetic knockout models or chemical 
inhibitors of PARP1, several studies provided direct evidence that PARP1-dependent par-
thanatos was functionally related to renal IRI and showed that inhibition of PARP1 could 
effectively improve renal injuries [60–62]. Besides in vivo models, upregulated PARP1 were 
also detected in cultured renal tubular epithelial cells that were subjected to H
2
O
2
 [60, 63]. 
In addition to renal ischemic injury, parthanatos also contributes to AKI induced by various 
nephrotoxic agents [64–66]. Furthermore, the contribution of parthanatos to AKI was deter-
mined in a LPS-induced sepsis-related kidney injury model [67–69]. Taken together, these 
studies exhibit that parthanatos is an important participant in different forms of AKI, indicat-
ing a promising therapeutic target in clinical routines.
4.3. Ferroptosis
Ferroptosis was discovered during a pharmacological intervention in highly resistant RAS-
transformed tumor cells with application of erastin by Dixon et al. [70]. Erastin, a lethal small mol-
ecule, was originally screened to eliminate cancer cells and was found to cause an unrecognized 
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type cell death that were distinct from either apoptosis, necroptosis, or other known regulated 
necrosis. This form of cell death, characterized by perioxidation, relies on accessible intracellular 
iron, and is therefore named as ferroptosis (ferro, ferrous ion) [70]. Erastin is believed to inhibit 
the system Xc- cystine/glutamate antiporter, which plays a key role in the exchange of extracel-
lular cystine and intracellular glutamate. Cystine is required for synthesizing glutathione (GSH). 
Glutathione peroxidase 4 (GPX4) is an indispensable enzyme maintaining intracellular homeosta-
sis by prevent reactive oxygen species accumulation and lipid peroxidation. Importantly, GPX4 is 
determined as a key inhibitor of ferroptosis, and its function is dependent on intracellular levels 
of GSH [71]. Therefore, inhibition of the system Xc- cystine/glutamate antiporter could result in 
a catastrophic decrease of GSH and thereby functional ablation of GPX4. More details about the 
emerging signaling of ferroptosis are provided by Yang and Stockwell [72]. Upon the introduction 
of ferroptosis, Dixon and Stockwell also identified a small molecule—ferrostatin-1—as an inhibi-
tor of ferroptosis, namely the first-generation of ferrostatins, which serves as a crucial tool in the 
research of ferroptosis thereafter [70]. Due to the pharmacological instability of ferrostatin-1, sec-
ond- and third-generation ferrostatins have been developed with promising therapeutic outlooks.
In 2014, three different teams from German and the United States reported that ferroptosis 
served as a crucial participant in the pathologic process of renal injuries. Friedmann Angeli 
and colleagues used inducible Gpx4 knockout mice to exhibit that deletion of Gpx4 led to 
ferroptosis-related acute renal failure and associated death. They also confirmed that Gpx4 
ablation could cause extra-mitochondrial lipid peroxidation which thereby triggered ferrop-
tosis. Furthermore, Liproxstatin-1, a spiroquinoxalinamine derivative, was demonstrated to 
inhibit ferroptosis in vitro and in vivo [73]. Rhabdomyolysis, as a severe and common clinical 
condition, is regarded as one of the main causes of AKI and rhabdomyolysis-induced AKI 
accounts for ~10% of all AKI cases. Rhabdomyolysis is the disruption of striped muscle fol-
lowed by massive releases of intracellular molecules, in particular electrolytes and myoglobin, 
which induces oxidative damages and cell death. Skouta et al. subjected freshly isolated mouse 
kidney proximal tubules to an ex vivo model of rhabdomyolysis-induced AKI with or without 
classic ferroptosis inhibitor Ferrostatin-1 and found that Ferrostatin-1 could effectively prevent 
cell death [74]. Linkermann et al. have found that ferroptosis contributed to the synchronized 
necrosis of freshly isolated renal tubules in the context of IRI and oxalate crystal-induced acute 
kidney injury and Ferrostatin-1could alleviate the synchronized necrosis. Linkermann and col-
leagues also developed a third generation ferrostatin 16–86 with a more stable biochemical and 
metabolic feature, which were able to protect mice from severe IRI [75]. These reports provide 
direct evidence for the vital importance of ferroptosis in the pathogenesis of several types of 
AKI, indicating a potential therapeutic checkpoint in treating renal diseases.
4.4. Pyroptosis
Pyroptosis was initially referred to a certain kind of highly inflammatory cell death of infected 
macrophages [76]. Later, the cellular profile of pyroptosis has expanded from macrophages 
to other cell types. It is notable that a distinct feature of pyroptosis is the active release of 
IL-1b and IL-18 during pyroptotic cell death process, which contributes greatly to the high 
immunogenicity of pyroptosis [77]. Although the signaling pathway of pyroptosis, especially 
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the execution mechanisms, still remains elusive now, it has been documented that pyrop-
totic cell death results from caspase 1-dependent formation of transmembrane channels 
and subsequent osmotic pressure disruption [78]. In addition to caspase 1, caspase 11 are 
further identified as another crucial mediator of pyroptosis [79, 80]. Pyroptosis can be sup-
pressed by chemical inhibitors VX-740, VX-765 as well as virus-derived molecule cytokine 
response modifier A (CrmA) [4, 76]. Few researches have focused on pyroptosis in the context 
of AKI. Yang et al. found that the expressions of pyroptosis-associated markers caspase 1 and 
caspase 11 were both significantly upregulated in a rat model of IRI and pyroptosis could 
also be observed in an in vitro model of hypoxia-reoxygenation, suggesting the existence of 
pyroptosis in kidney IRI [81]. Additionally, the authors demonstrated a possible regulation 
of endoplasmic reticulum (ER) stress on pyroptosis. But this interesting report provided no 
direct evidence for the functional responsibility of pyroptosis in renal injuries. The underly-
ing physiological and pathological relevance of pyroptosis in kidneys, therefore, still remains 
unclear and needs intensive investigations urgently in the future [82].
5. Therapeutic implications
5.1. Combination therapy
Anti-apoptosis-based therapeutic strategies have been intensively explored for the treatment 
of AKI prior to the recognition of regulated necrosis. However, few anti-apoptosis interven-
tions have been widely applied in clinical practice, despite the promising results obtained in 
animal models, which might be, at least partially, ascribed to our limited understanding of the 
regulated cell death in the context of AKI.
Thanks to the improved interpretation of the roles of regulated necrosis in kidney diseases, 
it is now possible to manipulate the apoptotic and regulated necrotic signaling simultane-
ously. In an interesting study, Tristao et al. found that the combined use of apoptosis and 
necroptosis inhibitors could provide additional protection in AKI, suggesting that the com-
bination therapy targeting apoptosis and regulated necrosis might provide optimized thera-
peutic alternatives [44]. Moreover, combined inhibition of different regulated necrosis is also 
effective. Linkermann et al. demonstrated that the third-generation ferroptosis inhibitor 16–86 
was able to further enhance the protective effect on IRI via combined treatment with necro-
statins and MPT-RN inhibitor [75]. These results indicate that the combined blocking of sev-
eral different regulated cell deaths hold the great promise to improve the current treatment 
for AKI. But further investigations are still needed.
5.2. Screening for next-generation inhibitors
Searching for chemical inhibitors or generating novel compounds targeting the critical check-
points makes it possible to manipulate regulated cell death more efficiently. Compared with 
apoptosis whose inhibitors have been widely explored, the inhibitors of regulated necrosis war-
rant more explorations in the future. For example, Nec-1 is the first-generation of necrostatins that 
initially identified as the RIP1 inhibitor, and later widely used as a tool to distinguish necroptosis. 
However, a recent study demonstrated that Nec-1 was not a specific inhibitor against necroptosis 
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because Nec-1 could also protect Rip1−/− cells from ferroptosis, indicating an inhibitory effect of 
Nec-1 on ferroptosis [73]. More seriously, unexpected side effects of Nec-1 were observed on 
renal peritubular diameters [47], and on the action of indolamin-2, 3-dioxygenase (IDO) [83]. 
Besides, a relatively short half-life period of Nec-1 also hampers its final clinical application [83]. 
Thus, Nec-1 is a typical example of the original edition of regulated necrosis inhibitors that are 
prevailingly nonspecific and pharmacologically unstable. Great efforts have been made to search-
ing for more effective and reliable inhibitors and a series of new inhibitors have been reported 
recently [34, 73, 75, 83–91]. It is remarkable that some researchers performed screens in the FDA-
approved agent pools to identify effective drugs to suppress necroptosis, providing a helpful 
screening strategy [84, 87]. Considering that FDA-approved drugs have already been carefully 
evaluated in critical procedures before the clinical application, their pharmacological features 
and side effects are well documented. Most “new” inhibitors have not been extensively evaluated 
and therefore need elaborate investigations in the near future. It is indeed exciting that increasing 
agents targeting regulated cell death have entered clinical trials for the treatment of AKI or other 
kidney diseases.
5.3. Paradigm shift of cell death
There has been an interesting finding published previously that the application of zVAD, a 
pan-caspase inhibitor, could shift the paradigm of cell death from apoptosis to necroptosis 
[43]. Researches have demonstrated that apoptosis and regulated necrosis could crosstalk 
at various molecular levels and therefore could mutually impact each other in some certain 
conditions. Therefore, researchers and clinicians should be cautious about the unwanted 
effect in designing cell death inhibition strategies. On the other side, however, it is also 
reasonable to consider whether the cell death paradigm shifting is a feasible therapeutic 
modality in AKI treatment. Theoretically, regulated necrosis, unlike apoptosis, can cause 
the massive release of DAMPs and are thus more inflammatory. Manipulating the cell death 
profile in favor of reducing structural and functional loss of individuals may provide an 
optimized treatment effect. This hypothesis, of course, warrants further investigations in the 
following studies.
6. Conclusions
Taken together, the programmed forms of cell death in AKI consist of apoptosis as well as 
regulated necrosis that both serve as crucial contributors in renal injuries. An updated and 
better understanding of the underlying mechanism of regulated cell death provides potential 
“checkpoints” for AKI treatment. Therapeutic regimens, targeting the regulated cell death, 
warrant intensive investigations in the near future.
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